(REGN)—Correction to #msg-111253341: NVS has not upsized its phase-3 trial of RTH258 vs Eylea from 1,000 to 1,700 patients; rather, NVS plans to start a second phase-3 trial with 700 patients, so the RTH258 phase-3 program will have approximately 1,700 patients. (H/t ‘Miljenko Zuanic’.)